Показано 0 из 0
Дата |
---|
10:42 |
02.07.2024 |
01.07.2024 |
28.06.2024 |
27.06.2024 |
26.06.2024 |
25.06.2024 |
24.06.2024 |
21.06.2024 |
20.06.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
4.31
|
5.08
|
5.12
|
5.06
|
5.12
|
5.06
|
|
|
5 015.20
|
2.00
|
4.41
|
5.08
|
4.31
|
4.31
|
4.98
|
4.98
|
|
|
1 245.00
|
2.00
|
4.33
|
5.08
|
5.42
|
4.02
|
5.42
|
4.70
|
|
|
127 110.35
|
23.00
|
5.66
|
6.30
|
5.96
|
5.96
|
6.00
|
6.00
|
|
|
8 094.00
|
6.00
|
5.96
|
6.86
|
5.96
|
5.96
|
5.96
|
5.96
|
|
|
|
|
6.20
|
6.88
|
6.08
|
6.08
|
6.08
|
6.08
|
|
|
|
|
6.06
|
6.40
|
6.00
|
6.00
|
6.80
|
6.80
|
|
|
2 040.00
|
2.00
|
6.00
|
6.80
|
6.40
|
6.40
|
6.40
|
6.40
|
|
|
|
|
6.52
|
7.00
|
6.56
|
6.56
|
6.62
|
6.60
|
|
|
1 848.60
|
4.00
|
6.54
|
7.00
|
6.74
|
6.54
|
6.74
|
6.54
|
|
|
1 064.28
|
3.00
|
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company’s drugs are intended to provide patients with various treatment options. Its pipeline is protected by a portfolio of patents and comprises three principal drug candidates that are in various stages of development.